Drug Trial Radar · NCT07342114
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Mar 11, 2026
Primary completion
Jun 17, 2030
Study completion Jun 17, 2030
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants. Part B: The purpose of Part B of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RO7875913 administered in combination with the T cell-engaging bispecific antibody (TCB) cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).
Conditions
- Healthy Volunteers
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
Interventions
RO7875913Drug
Participants will receive RO7875913 as per the schedule described in the protocol.
PlaceboDrug
Participants will receive placebo as per the schedule described in the protocol.
CevostamabDrug
Participants will receive cevostamab as per the schedule described in the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants with Adverse Events (AEs)Time frame: Up to approximately 3 months
- Part B: Percentage of Participants with Adverse Events (AEs)Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research - Christchurch
Christchurch, Canterbury, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.